View Author
stent patient trial stent thrombosis study thrombosis event diabetes death lesion outcome hospital target definition revascularization vessel artery implantation randomized table point treatment group follow-up heart sirolimus-eluting result drug-eluting cardiol circulation procedure research analysis month intervention incidence infarction disease drug-eluting stents sirolimus-eluting stents end points coll cardiol artery disease endpoint pre-speci safety performance goal device cohort diabetes mellitus 5 years 30 days leon mb angiographic signi criteria swets subscription service target lesion finition antiplatelet therapy signi ficantly insulin mellitu zotarolimus-eluting end point definitions target vessel consensus therapy value center university ravel index procedure randomized comparison stent apposition number sirolimus-eluting stent medtronic investigator performance
6 Most Recent Publications
|
Impact of Overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: Pooled analysis of five trials from the international Global Resolute Program
(Article)
Farooq, V. Vranckx, P. Negoita, M. Leeuwen, A.F. van Neumann, F.J. Yeung, A.C. Garcia-Garcia, H.M. Serruys, P.W.J.C. Mauri, L. Cutlip, D.E. Belardi, J.A. Silber, S. Widimsky, P. Leon, M.B. Windecker, S. Meredith, I. |
2013-05-01
|
|
Clinical Outcome of Patients With and Without Diabetes Mellitus After Percutaneous Coronary Intervention With the Resolute Zotarolimus-Eluting Stent. 2-Year Results From the Prospectively Pooled Analysis of the International Global RESOLUTE Program
(Article)
Silber, S. Serruys, P.W.J.C. Yeung, A.C. Saito, S. Mauri, L. Leon, M.B. Meredith, I. Windecker, S. Neumann, F.J. Belardi, J.A. Widimsky, P. Massaro, J. Novack, V. |
2013-03-21
|
|
Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): Randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation
(Article)
Camenzind, E. Wijns, W. O'Neill, W.W. Serruys, P.W.J.C. Jorissen, B. Steg, P.G. Mauri, L. Boersma, H. Parikh, K. Kurowski, V. Gao, R. Bode, C. Greenwood, J.P. Gershlick, A. |
2009-12-01
|
|
Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: Intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials
(Article)
Hoffmann, R. Morice, M-C. Moses, J.W. Fitzgerald, P.J. Mauri, L. Breithardt, G. Schofer, J. Serruys, P.W.J.C. Stoll, H.P. Leon, M.B. |
2008-03-01
|
|
Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents. Five-Year Results of the RAVEL Trial
(Article)
Morice, M-C. Serruys, P.W.J.C. Barragan, P. Bode, C. Es, G.A. van Stoll, H.P. Snead, D. Mauri, L. Cutlip, D.E. Sousa, E. |
2007-10-01
|
|
Clinical end points in coronary stent trials: A case for standardized definitions
(Article)
Cutlip, D.E. Windecker, S. McFadden, E.P. Lansky, A.J. Hamon, M. Krucoff, M. Serruys, P.W.J.C. Mehran, R. Boam, A. Cohen, D.J. Es, G.A. van Steg, P.G. Morel, M-A.M. Mauri, L. Vranckx, P. |
2007-05-01
|
